Roche and Ionis Report Sefaxersen Met 37-Week Proteinuria Endpoint in Phase 3 IMAgINATION Interim Analysis in IgA Nephropathy
Roche said on September 23, 2026 that a prespecified interim analysis of the Phase 3 IMAgINATION trial found sefaxersen produced a statistically significant reduction in 24-hour urine protein-to-creatinine ratio versus placebo at 37 weeks in adults with primary IgA nephropathy at high risk of progression. The trial randomized 459 people 1:1 to sefaxersen, a once-monthly subcutaneous antisense drug that reduces liver production of complement factor B, or to placebo for 105 weeks. Roche did not disclose the size of the proteinuria reduction; the trial remains blinded to week 105 to measure change in eGFR, and safety was consistent with prior data. Roche licensed sefaxersen from Ionis.